Phospho	O
-	O
MED1	O
-	O
enhanced	O
UBE2C	O
locus	O
looping	O
drives	O
castration	O
-	O
resistant	O
prostate	O
cancer	O
growth	O
.	O


The	O
UBE2C	O
oncogene	O
is	O
overexpressed	O
in	O
many	O
types	O
of	O
solid	O
tumours	O
including	O
the	O
lethal	O
castration	O
-	O
resistant	O
prostate	O
cancer	O
(	O
CRPC	O
)	O
.	O


The	O
underlying	O
mechanisms	O
causing	O
UBE2C	O
gene	O
overexpression	O
in	O
CRPC	O
are	O
not	O
fully	O
understood	O
.	O


Here	O
,	O
we	O
show	O
that	O
CRPC	O
-	O
specific	O
enhancers	O
drive	O
UBE2C	O
overexpression	O
in	O
both	O
AR	O
-	O
negative	O
and	O
-	O
positive	O
CRPC	O
cells	O
.	O


We	O
further	O
show	O
that	O
co	O
-	O
activator	O
MED1	O
recruitment	O
to	O
the	O
UBE2C	B-ENHANCER
enhancers	E-ENHANCER
is	O
required	O
for	O
long	O
-	O
range	O
UBE2C	O
enhancer	O
/	O
promoter	O
interactions	O
.	O


Importantly	O
,	O
we	O
find	O
that	O
the	O
molecular	O
mechanism	O
underlying	O
MED1	O
-	O
mediated	O
chromatin	O
looping	O
involves	O
PI3K	O
/	O
AKT	O
phosphorylated	O
MED1	O
-	O
mediated	O
recruitment	O
of	O
FoxA1	O
,	O
RNA	O
polymerase	O
II	O
and	O
TATA	O
binding	O
protein	O
and	O
their	O
subsequent	O
interactions	O
at	O
the	O
UBE2C	O
locus	O
.	O


MED1	O
phosphorylation	O
leads	O
to	O
UBE2C	O
locus	O
looping	O
,	O
UBE2C	O
gene	O
expression	O
and	O
cell	O
growth	O
.	O


Our	O
results	O
not	O
only	O
define	O
a	O
causal	O
role	O
of	O
a	O
post	O
-	O
translational	O
modification	O
(	O
phosphorylation	O
)	O
of	O
a	O
co	O
-	O
activator	O
(	O
MED1	O
)	O
in	O
forming	O
or	O
sustaining	O
an	O
active	O
chromatin	O
structure	O
,	O
but	O
also	O
suggest	O
that	O
development	O
of	O
specific	O
therapies	O
for	O
CRPC	O
should	O
take	O
account	O
of	O
targeting	O
phosphorylated	O
MED1	O
.	O
